PURPOSE: In this retrospective multicenter study, the authors analyzed the clinical efficacy of different metallic stents in the palliative treatment of patients with neoplastic obstructive jaundice. PATIENTS AND METHODS: Two hundred forty patients were treated in four European centers. Causes of obstruction were pancreatic carcinoma (n = 84), biliary neoplasm (n = 99), metastases in hilar nodes (n = 34), primary or secondary liver tumors (n = 4), and other tumors (n = 19). A total of 388 metallic stents were used: 300 Wallstents, 35 nitinol Strecker stents, 40 Gianturco-Rosch Z stents, and 13 tantalum Strecker stents. RESULTS: Overall 25- and 50-week survival rates were 42% and 16%, respectively; the 30-day mortality rate was 14.6%. Two deaths were related to the procedure (0.8%); 19 patients (8%) had major complications. The 25-week patency rate was significantly higher for the nitinol Strecker stents and the Wallstents (78% and 67%, respectively) than for the Z stents and the tantalum Strecker stents (30% and 20%, respectively) (P < .01 and P < .001, respectively). Average patency was 8.3, 5.9, 2.3, and 4.0 months, respectively. Reintervention due to stent obstruction was necessary in 53 patients. CONCLUSION: The Wallstent and the nitinol Strecker stents were the most effective in achieving long-term palliation. Patency was significantly affected by the level of obstruction but not by the type of obstructing tumor.
PURPOSE: In this retrospective multicenter study, the authors analyzed the clinical efficacy of different metallic stents in the palliative treatment of patients with neoplastic obstructive jaundice. PATIENTS AND METHODS: Two hundred forty patients were treated in four European centers. Causes of obstruction were pancreatic carcinoma (n = 84), biliary neoplasm (n = 99), metastases in hilar nodes (n = 34), primary or secondary liver tumors (n = 4), and other tumors (n = 19). A total of 388 metallic stents were used: 300 Wallstents, 35 nitinol Strecker stents, 40 Gianturco-Rosch Z stents, and 13 tantalum Strecker stents. RESULTS: Overall 25- and 50-week survival rates were 42% and 16%, respectively; the 30-day mortality rate was 14.6%. Two deaths were related to the procedure (0.8%); 19 patients (8%) had major complications. The 25-week patency rate was significantly higher for the nitinol Strecker stents and the Wallstents (78% and 67%, respectively) than for the Z stents and the tantalum Strecker stents (30% and 20%, respectively) (P < .01 and P < .001, respectively). Average patency was 8.3, 5.9, 2.3, and 4.0 months, respectively. Reintervention due to stent obstruction was necessary in 53 patients. CONCLUSION: The Wallstent and the nitinol Strecker stents were the most effective in achieving long-term palliation. Patency was significantly affected by the level of obstruction but not by the type of obstructing tumor.
Authors: Won Jae Yoon; Ji Kon Ryu; Jung Won Lee; Dong-Won Ahn; Yong-Tae Kim; Yong Bum Yoon; Sang Myung Woo; Woo Jin Lee Journal: World J Gastroenterol Date: 2010-11-14 Impact factor: 5.742
Authors: B A Radeleff; R López-Benítez; P Hallscheidt; L Grenacher; M Libicher; G M Richter; G W Kauffmann Journal: Radiologe Date: 2005-11 Impact factor: 0.635
Authors: Steve M M de Castro; Koert F D Kuhlmann; Olivier R C Busch; Otto M van Delden; Johan S Laméris; Thomas M van Gulik; Hugo Obertop; Dirk J Gouma Journal: J Gastrointest Surg Date: 2005-11 Impact factor: 3.452
Authors: Petra G A van Boeckel; Ewout W Steyerberg; Frank P Vleggaar; Marcel J M Groenen; Ben J M Witteman; Bas L A M Weusten; Han Geldof; Adriaan C I T L Tan; Marina J A L Grubben; Jan Nicolai; Peter D Siersema Journal: J Gastroenterol Date: 2011-07-14 Impact factor: 7.527